An intravenous, glycoengineered type I anti‑CD20 monoclonal antibody immunotherapy that selectively binds CD20 on B cells and depletes them primarily via enhanced antibody‑dependent cellular cytotoxicity, with contributions from complement‑dependent cytotoxicity and apoptosis; targets pre‑B and mature CD20+ B lymphocytes (sparing plasma cells) to reduce antigen presentation, costimulation, and proinflammatory cytokine signaling in multiple sclerosis.